AngioDynamics initiated with a Buy at Lake Street

Lake Street initiated coverage of AngioDynamics (ANGO) with a Buy rating and $24 price target The firm says the company has transformed its portfolio into faster-growth and higher-margin cardiovascular and cancer treatment products. The Street is missing AngioDynamics’ strategic realignment as the shares should be valued more in line with higher multiple medical technology companies, the analyst tells investors in a research note.